The inhibitory effect of PLGA-encapsulated berberine on hepatotoxicity and α-smooth muscle actin (α-SMA) gene expression.
Actins
/ genetics
Alanine Transaminase
/ blood
Animals
Aspartate Aminotransferases
/ blood
Berberine
/ pharmacology
Carbon Tetrachloride
Gene Expression Regulation
/ drug effects
Liver
/ drug effects
Male
Nanoparticles
/ chemistry
Particle Size
Polylactic Acid-Polyglycolic Acid Copolymer
/ chemistry
RNA, Messenger
/ genetics
Rats, Wistar
Spectroscopy, Fourier Transform Infrared
Static Electricity
Berberine
Liver injury
PLGA nanoparticles
α–smooth muscle actin
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
received:
07
05
2021
revised:
03
08
2021
accepted:
06
08
2021
pubmed:
15
8
2021
medline:
6
10
2021
entrez:
14
8
2021
Statut:
ppublish
Résumé
Liver injury results in excessive extracellular matrix (ECM) deposition in the liver, which is mainly produced by hepatic stellate cells (HSC). Alpha-smooth muscle actin (α-SMA) and liver enzymes are the two hallmarks of liver injury. Previously, it has been confirmed that berberine (BBR) attenuates liver injury. This study aimed to investigate the protective effect of Poly Lactic-co-Glycolic Acid (PLGA) encapsulated BBR against liver injury. Nanoprecipitation, encapsulation, and physio-chemical characterization of BBR-PLGA nanoparticles (BBR-PLGA-NP) have been done. The protective effects of BBR-PLGA-NPs and BBR against carbon tetrachloride (CCl4)-treated Wistar rats were investigated. The serum levels of alanine aminotransferase and aspartate transaminase were measured, and the expression level of α-SMA was quantified by qRT-PCR. To evaluate the liver changes, morphological and histological staining was done. BBR-PLGA-NPs markedly reduced serum ALT and AST in rats treated with CCl The use of nanoparticle to encapsulate BBR is a worthy approach to enhance the curative effect of BBR against liver injuries, which donate a safe and effective drug delivery strategy to treat liver injuries.
Sections du résumé
BACKGROUND
BACKGROUND
Liver injury results in excessive extracellular matrix (ECM) deposition in the liver, which is mainly produced by hepatic stellate cells (HSC). Alpha-smooth muscle actin (α-SMA) and liver enzymes are the two hallmarks of liver injury. Previously, it has been confirmed that berberine (BBR) attenuates liver injury. This study aimed to investigate the protective effect of Poly Lactic-co-Glycolic Acid (PLGA) encapsulated BBR against liver injury.
METHODS
METHODS
Nanoprecipitation, encapsulation, and physio-chemical characterization of BBR-PLGA nanoparticles (BBR-PLGA-NP) have been done. The protective effects of BBR-PLGA-NPs and BBR against carbon tetrachloride (CCl4)-treated Wistar rats were investigated. The serum levels of alanine aminotransferase and aspartate transaminase were measured, and the expression level of α-SMA was quantified by qRT-PCR. To evaluate the liver changes, morphological and histological staining was done.
RESULTS
RESULTS
BBR-PLGA-NPs markedly reduced serum ALT and AST in rats treated with CCl
CONCLUSION
CONCLUSIONS
The use of nanoparticle to encapsulate BBR is a worthy approach to enhance the curative effect of BBR against liver injuries, which donate a safe and effective drug delivery strategy to treat liver injuries.
Identifiants
pubmed: 34389401
pii: S0024-3205(21)00871-7
doi: 10.1016/j.lfs.2021.119884
pii:
doi:
Substances chimiques
Acta2 protein, rat
0
Actins
0
RNA, Messenger
0
Berberine
0I8Y3P32UF
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Carbon Tetrachloride
CL2T97X0V0
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119884Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.